Linked Life Data

19644802

Source:http://linkedlifedata.com/resource/pubmed/id/19644802

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2009-7-31
pubmed:abstractText
Diabetic retinopathy is the leading cause of vision loss or blindeness in working-age adults in the developed and developing countries. No curative treatments are available for diabetic retinopathy and the most common symptomatic treatment, laser photocoagulation, provides only partial and temporary relief from the progressive vascular damage caused by this disease. Etofibrate (Lipo-Merz) is an orally-administered treatment for lipid disorders that combines fibrate and nicotinic acid in a slow-release formulation.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1439-3999
pubmed:author
pubmed:copyrightInfo
Georg Thieme Verlag KG Stuttgart, New York
pubmed:issnType
Electronic
pubmed:volume
226
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
561-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
pubmed:affiliation
Augenklinik, Klinikum Darmstadt, Darmstadt. augenklinik@klinikumdarmstadt.de
pubmed:publicationType
Journal Article, English Abstract, Randomized Controlled Trial